Younger Breast Cancer Patients at Higher Risk for Osteoporosis

Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified

Gly101Val Mutation Directly Causes Resistance to Venetoclax

Can Treatments for Childhood ALL Alter the Gut Microbiome?

Olaratumab May Be Safe and Effective in Patients With Advanced Soft Tissue Sarcoma

Next-Generation Sequencing May Benefit Some Patients With Sarcoma

Continuous Therapy May Be Beneficial in Patients With Newly Diagnosed Multiple Myeloma

Tecentriq Combination Regimen Approved for Metastatic Non-Squamous NSCLC

Risk Score Identifies Adjuvant Chemotherapy Toxicity Risk in Elderly Patients With Breast Cancer

Despite Breast-Conserving Surgery Eligibility, Nearly 50% of Women Chose Mastectomy

Does Epigenetic Therapy With Panobinostat Reduce CRPC Bicalutamide Resistance?

Panobinostat plus bicalutamide increased radiographic progression-free survival in patients with CRPC resistant to second-line antiandrogen therapy.

Nivolumab Monotherapy Provides Long-Term Benefit Advanced Melanoma

Dacarbazine, although once a staple of melanoma therapy, essentially has no current role in the treatment of any type or stage of melanoma.

EUTOS Long-Term Survival Score Outperforms Sokal in TKI-Treated CML

EUTOS long-term survival score better predicted prognosis for those with chronic myeloid leukemia who had been treated with TKIs—especially among elderly patients.